Scholarlink

Background <p>Gastric cancer (GC) remains a significant global health burden due to its high incidence and mortality, especially in China. This study aimed to evaluate the performance of combined serological assessment of pepsinogen (PG) and <i>Helicobacter pylori</i> (<i>H. pylori</i>) antibodies for identifying gastric precancerous conditions.</p> Methods <p>From November 2016 to September 2019, an observational cohort study was performed to evaluate serum levels of PG and <i>H. pylori</i> antibodies. Among 19,879 participants, four groups were defined based on serological status: Group A (PG<sup>–</sup>/ <i>H. pylori</i><sup>–</sup>), Group B (PG<sup>–</sup>/ <i>H. pylori</i><sup>+</sup>), Group C (PG<sup>+</sup>/ <i>H. pylori</i><sup>+</sup>), and Group D (PG<sup>+</sup>/ <i>H. pylori</i><sup>–</sup>). Participants from Groups C and D were included in the analysis, while individuals from Groups A and B were randomly selected at a 3:1 ratio relative to Groups D and C, respectively. In total, 1,152 subjects underwent endoscopic and histopathological assessment.</p> Results <p>Group C demonstrated significantly elevated odds of atrophic gastritis (AG) (OR = 1.98; 95% CI: 1.17–3.26) and intestinal metaplasia (IM) (OR = 1.40; 95% CI: 0.73–2.67) compared to Group A. In the gastric corpus, the odds of AG and IM were 5.0 and 6.8 times higher, respectively, in Group C versus Group A.</p> Conclusion <p>Combined serological assessment of PG and anti- <i>H. pylori</i> IgG improves the identification of gastric precancerous conditions, with particularly enhanced performance in the gastric corpus.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrating serological markers of Helicobacter pylori and pepsinogen to improve detection of gastric precancerous conditions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Zetian Chen,
  • Hongxin Huang,
  • Huimin Tao,
  • Rui Wu,
  • Zekuan Xu,
  • Qiang Zhan,
  • Zheng Li

摘要

Background

Gastric cancer (GC) remains a significant global health burden due to its high incidence and mortality, especially in China. This study aimed to evaluate the performance of combined serological assessment of pepsinogen (PG) and Helicobacter pylori (H. pylori) antibodies for identifying gastric precancerous conditions.

Methods

From November 2016 to September 2019, an observational cohort study was performed to evaluate serum levels of PG and H. pylori antibodies. Among 19,879 participants, four groups were defined based on serological status: Group A (PG–/ H. pylori–), Group B (PG–/ H. pylori+), Group C (PG+/ H. pylori+), and Group D (PG+/ H. pylori–). Participants from Groups C and D were included in the analysis, while individuals from Groups A and B were randomly selected at a 3:1 ratio relative to Groups D and C, respectively. In total, 1,152 subjects underwent endoscopic and histopathological assessment.

Results

Group C demonstrated significantly elevated odds of atrophic gastritis (AG) (OR = 1.98; 95% CI: 1.17–3.26) and intestinal metaplasia (IM) (OR = 1.40; 95% CI: 0.73–2.67) compared to Group A. In the gastric corpus, the odds of AG and IM were 5.0 and 6.8 times higher, respectively, in Group C versus Group A.

Conclusion

Combined serological assessment of PG and anti- H. pylori IgG improves the identification of gastric precancerous conditions, with particularly enhanced performance in the gastric corpus.